PTC Therapeutics, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 538.59M | 698.80M | 937.82M | 806.78M | 1.73B | 114.5% | |
| Cost of Revenue | (32.33M) | (44.68M) | (65.49M) | (57.40M) | (71.75M) | 25.0% | |
Gross Profit | 506.26M | 654.12M | 872.34M | 749.38M | 1.66B | 121.4% | |
| Operating Expenses | |||||||
| Research & Development | (540.68M) | (651.50M) | (666.56M) | (534.48M) | (455.25M) | -14.8% | |
| Selling, General & Administrative | (285.77M) | (326.00M) | (332.54M) | (300.91M) | (347.14M) | 15.4% | |
| Depreciation & Amortization | (64.13M) | (128.84M) | (236.59M) | (75.66M) | (38.81M) | -48.7% | |
Operating Income (EBIT) | -374.44M | -447.41M | -439.50M | -302.57M | 856.51M | -383.1% | |
| Non-Operating Items | |||||||
| Interest Income | — | — | — | — | — | — | |
| Interest Expense | (86.02M) | (90.87M) | (129.18M) | (166.99M) | (152.23M) | -8.8% | |
| Other Income/Expenses (Net) | -143.90M | -140.08M | -256.61M | -60.55M | -159.89M | 164.1% | |
Income Before Tax | -518.34M | -587.49M | -696.11M | -363.12M | 696.62M | -291.8% | |
| Income Tax Expense | (5.56M) | (28.47M) | (69.51M) | (176.00K) | (13.97M) | 7840.3% | |
Net Income | -523.90M | -559.02M | -626.60M | -363.30M | 682.64M | -287.9% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $-7 | $-8 | $-8 | $-5 | $9 | -281.4% | |
| Weighted Avg Shares Outstanding | 70.47M | 71.73M | 74.84M | 76.85M | 79.53M | 3.5% | |
| Weighted Avg Shares Outstanding (Diluted) | 70.47M | 71.73M | 74.84M | 76.85M | 88.31M | 14.9% | |
EBITDA | -368.18M | -367.78M | -330.34M | -120.46M | 887.66M | -836.9% |
Explore PTCT
PTCT in the Healthcare
Mid Cap